Shattuck Labs submitted an Investigational New Drug (IND) application for SL-325 to FDA, expecting clearance in Q3 2025. They plan to dose the first participant in the Phase 1 clinical trial for SL-325 in the same quarter. With a cash balance of approximately $50.5 million at the end of Q2 2025, they anticipate funding operations into 2029 with proceeds from a recent private placement of up to $103 million.

Shattuck’s lead product candidate, SL-325, is a DR3 blocking antibody for inflammatory diseases. An IND for SL-325 was submitted in July 2025, with Phase 1 trials in healthy volunteers expected to start in Q3 2025. Shattuck also plans to nominate a lead bispecific candidate from its preclinical pipeline in 2025.

Financially, Shattuck reported $50.5 million in cash and cash equivalents at the end of Q2 2025. Research and Development expenses were $8.7 million, while General and Administrative expenses were $4.4 million for the same period. The net loss for Q2 2025 was $12.5 million.

With cash and cash equivalents of $50.5 million as of June 30, 2025, Shattuck anticipates that the proceeds from the recent private placement, combined with existing funds, will fund operations into 2029. The company plans to use these funds for the clinical development of SL-325, including Phase 2 trials in Inflammatory Bowel Disease and general corporate purposes.

SL-325, a potential first-in-class DR3 blocking antibody, aims to block the DR3/TL1A pathway effectively. Preclinical studies show high affinity binding and superior activity over TL1A antibodies. Shattuck plans to start a Phase 1 clinical trial in healthy volunteers in Q3 2025. Shattuck Labs specializes in developing treatments for inflammatory and immune-mediated diseases, with offices in Austin, Texas, and Durham, North Carolina.

Read more at GlobeNewswire: Shattuck Labs Reports Second Quarter 2025 Financial Results